Helsinn Provides Grant for ESMO's Preceptorship Course on

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
129
Helsinn Provides Grant for ESMO's Preceptorship Course on Supportive and Palliative Care

Helsinn Provides Grant for ESMO's Preceptorship Course on Supportive and Palliative Care

Lugano, Switzerland, February 15, 2017 - Helsinn, a Swiss pharmaceutical group focused on building quality cancer care, announces that the Group has provided a grant to the European Society for Medical Oncology ("ESMO") for a preceptorship event dedicated to supportive and palliative care for physicians.

The preceptorship course will take place in Zurich on February 20-21, 2017 and will touch on a broad range of aspects related to cancer supportive and palliative care. The key learning objectives of the preceptorship are to:

  • Understand mechanisms of the key symptoms and syndromes: pain, fatigue, anorexia, nausea, vomiting, diarrhea, constipation, mucositis, depression and breathlessness, and their association with cancer disease and anticancer-treatment
  • Describe the main pharmacological, physical, educational, communicative and coordinate interventions for management of the syndromes of cachexia and malnutrition, and key symptoms
  • Understand integration of screening for, and assessment of, symptoms and other palliative/supportive care needs, and management in routine oncology care
  • Describe required competences of multidisciplinary teams for multimodal management
  • Understand the key issues of cancer rehabilitation
  • Understand bone health in cancer patients
  • Understand the risk and management of venous Thromboembolism in cancer patients
  • Understand Cardiotoxicity and its management in the area of targeted agents
  • Learn the ESMO Clinical Practice Guidelines relevant for the topics discussed

The Chair of the event will be Dr Florian Strasser MD, Associate Professor in the Clinic Oncology/Hematology at the Cantonal Hospital St. Gallen, Head of Oncological Palliative Medicine at Cantonal Hospital St Gallen, Switzerland, where he is responsible for the clinical and research activities in Palliative Oncology and in Geriatric Oncology. He is also substantially involved in Geriatric Oncology, Supportive Care and Cancer Rehabilitation for both in- and out-patients in the Comprehensive Cancer Center.

The co-Chair is Dr Karin Jordan who, since 2010, has been Associate Professor of Medical Oncology and Supportive Care in the Department of Oncology/Haematology at the University Hospital, Halle, and who has just recently changed position and is now working at the University of Heidelberg.

The event is expected to be attended by members of ESMO from around the world. The aim of these educational courses, which focus on teaching standard of care in specific areas, is to provide "state of the art" lectures in an interactive setting including formal presentations and interaction between experts and attendees presenting clinical cases.

The full meeting program is available here .

Sergio Cantoreggi, Helsinn Group Chief Scientific Officer, said: " At Helsinn we are delighted to be able to provide a grant to ESMO to work with physicians and further advance supportive and palliative care through this Preceptorship Course. This event will help foster relationships between senior, experienced physicians, and those at the start of their careers, meaning that patients will receive the best possible supportive care to help them live with cancer on a day to day basis."

Dr Florian Strasser MD, Chair of the Preceptorship Course on Supportive and Palliative Care, commented: "I am delighted this event dedicated to both supportive and palliative care has been organized, and I thank those at Helsinn for their generous and fully unrestricted support in helping us establish this. Supportive and palliative care is an area of oncology that does not receive enough merit increasing attention in modern, personalized oncology and this event will help to address this problem."

-Ends-

About the Helsinn Group

Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a broad development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Ireland and the US, a representative office in China as well as a product presence in about 90 countries globally. For more information, please visit www.helsinn.com .

About ESMO

ESMO is the leading professional organisation for medical oncology. With 15,000 members representing oncology professionals from over 130 countries worldwide, ESMO is the society of reference for oncology education and information. We are committed to supporting our members to develop and advance in a fast-evolving professional environment.

www.esmo.org

Helsinn Group Contact:

Paola Bonvicini

Head of Communication & Press Office

+41 91-985-21-70

info-hhc@helsinn.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 135

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 220

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 210

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 318

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 269

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 283

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 406

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 180

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 103

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 235

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading

Top 5 Most Recently Viewed Articles

Sandler Partners Unveils 2025 Superstar Trip Destination

Updated Category News Views 179

Sandler Partners Unveils 2025 Superstar Trip Destination Sandler Partners is thrilled to reveal the highly anticipated location for its 2025 Superstar Trip, a special reward designed to honor Partners who have excelled in achieving their growth objectives for the year. The trip will take place at the stunning Susurros del Corazón Resort, located along the picturesque...

Continue Reading
e.l.f. Beauty Stock Insights: Understanding Market Trends Today

Updated Category News Views 309

Market Sentiment Surrounding e.l.f. Beauty Investors with substantial capital are showing a cautious approach towards e.l.f. Beauty (NYSE: ELF). This sentiment isn't just noise in the market; it reflects deeper strategies that should be on the radar of traders and analysts alike. There has been significant insight gleaned from public options activity which suggests that...

Continue Reading
Empowering Teens Through Free AI Bootcamp by Mark Cuban

Updated Category News Views 216

Empowering Teens Through Innovative AI Bootcamp Time is of the essence for high school students eager to launch their careers in technology with the Mark Cuban Foundation's Artificial Intelligence (AI) Bootcamp. Hosted by Girls Inc., this remarkable initiative opens doors for teens interested in the cutting-edge realm of AI. Applications for participation are set to close...

Continue Reading
BlackRock's Major Acquisition of Global Infrastructure Partners

Updated Category News Views 275

BlackRock Secures $12.5 Billion Deal The U.S. Federal Energy Regulatory Commission has recently approved BlackRock's substantial acquisition of Global Infrastructure Partners, valued at $12.5 billion. This approval is a pivotal moment for BlackRock as it seeks to broaden its reach within the infrastructure investment sector. Details of the Acquisition In this significant...

Continue Reading
Key Analyst Initiations Impacting Major Stocks This Week

Updated Category News Views 120

Recent Analyst Initiations: An Overview In the dynamic realm of stock trading, the insights of analysts can have a major impact on market trends. Recently, Wall Street has made significant adjustments to their ratings for several well-known stocks. Below, we summarize the latest analyst actions that may affect investor decisions this week. Arm Holdings plc (NASDAQ: ARM)...

Continue Reading